{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:50:31Z","timestamp":1777517431304,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ygyno.2019.11.010","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T12:10:10Z","timestamp":1578053410000},"page":"265-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies"],"prefix":"10.1016","volume":"156","author":[{"given":"Thomas J.","family":"Herzog","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Wendel","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.ygyno.2019.11.010_bib1","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"LBA2_PR Phase III PAOLA-1\/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.11.010_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1910962","article-title":"Investigators PE-OG-. Niraparib in patients with newly diagnosed advanced ovarian cancer","author":"Gonzalez-Martin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.11.010_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.11.010_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.058","article-title":"LBA61A randomized phase II\/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer","volume":"30","author":"Gershenson","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib5","article-title":"1 MILO\/ENGOT-OV11: phase-3 study of binimetinib versus physician\u2019s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"29","author":"Grisham","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2019.11.010_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2019.11.010_bib7","author":"KEYTRUDA\u00ae"},{"key":"10.1016\/j.ygyno.2019.11.010_bib8","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.2016.67.8722","article-title":"Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG oncology\/gynecologic oncology group study","volume":"34","author":"McMeekin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib9","article-title":"1044P Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study","volume":"30","author":"O\u2019Malley","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib10","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.5520","article-title":"A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes","volume":"31","author":"Vergote","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz250.002","article-title":"994O Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)","volume":"30","author":"Makker","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2019.11.010_bib16","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib17","first-page":"JCO1900739","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II CheckMate 358 trial","author":"Naumann","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib18","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz250.062","article-title":"1054P Prognostic and clinicopathological significance of PD-L1 in patients with cervical cancer: a meta-analysis","volume":"30","author":"Gu","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.059","article-title":"LBA62 Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent\/metastatic (R\/M) cervical cancer: results from CheckMate 358","volume":"30","author":"Naumann","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib21","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.11.010_bib22","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.11.010_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.055","article-title":"LBA58 barocco: a randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC)","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.057","article-title":"LBA60 Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC)","volume":"30","author":"Konstantinopoulos","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz250.001","article-title":"993O OCTOPUS: a randomised, multi-centre phase II umbrella trial of weekly paclitaxel+\/- novel agents in platinum-resistant ovarian cancer: Vistusertib","volume":"30","author":"Banerjee","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.11.010_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz250","article-title":"992O forward I (GOG 3011): a phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)","volume":"30","author":"Moore","year":"2019","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819316397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819316397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:49:03Z","timestamp":1758772143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819316397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0090825819316397"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.11.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}